Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs

Giuliani Jacopo; Bonetti Andrea

首页> 外文期刊>Clinical lung cancer >Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs

【24h】

Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs

机译：Nivolumab在二线治疗中进行高级非小细胞肺癌，鳞状细胞组织学：基于药理成本的透视

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical lung cancer》 |2017年第5期|共3页
作者
Giuliani Jacopo; Bonetti Andrea;
展开▼
作者单位

Mater Salutis Hosp Dept Oncol Veneto Legnago Italy;

Mater Salutis Hosp Dept Oncol Veneto Legnago Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Cost of drugs; ESMO-MCBS; Randomized phase 3 trials; Second-line therapy; Targeted therapies;

机译：药物成本;ESMO-MCB;随机阶段3试验;二线治疗;有针对性的疗法;

相似文献

外文文献
中文文献
专利

1. Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs [J] . Giuliani Jacopo, Bonetti Andrea Clinical lung cancer . 2017,第5期

机译：Nivolumab在二线治疗中进行高级非小细胞肺癌，鳞状细胞组织学：基于药理成本的透视
2. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models [J] . Lan Gao, Shu-Chuen LI Applied health economics and health policy . 2019,第3期

机译：使用双重救生和马尔可夫模型进行澳大利亚二线高龄或转移性鳞状非小细胞肺癌的核心水平的经济评价
3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J] . Brahmer Julie, Reckamp Karen L., Baas Paul, The New England journal of medicine . 2015,第2期

机译：Nivolumab与高等鳞状细胞非小细胞肺癌中的多西紫杉醇
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers [O] . Matthieu Dusselier, Elise Deluche, Nellie Delacourt, 2012

机译：中性粒细胞与淋巴细胞比率的演变是二线尼古鲁单抗治疗的晚期非小细胞肺癌患者早期进展的独立预测因子
7. PUB002 Nivolumab in Second-Line Treatment for Advanced Non-Small Cell Lung Cancer with Squamous Cell Histology: A Cost-Effective Choice [O] . J. Giuliani, A. Bonetti 2017

机译：PUB002 Nivolumab在二线治疗中进行高级非小细胞肺癌，具有鳞状细胞组织学：一种经济有效的选择

Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs

著录项

相似文献

相关主题

期刊订阅